BioSpace News Archive

Livongo Health, the leading consumer digital health company empowering people with chronic conditions to live better and healthier lives, announced today it has acquired Chicago-based Retrofit, a leading provider of weight-management and disease-prevention programs.

Stoke Therapeutics, Inc., a biotechnology company developing therapeutics that increase gene expression to treat a wide array of diseases caused by genetic insufficiency, today announced the expansion of its leadership team to enhance its deep expertise in oligonucleotide chemistry and rare disease research and development.

Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases, announced today that the company will present five scientific posters at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid, Spain from April 21 – 24, 2018

PharmaMar (MCE: PHM) has presented during the AACR meeting (American Association for Cancer Research) in Chicago new data about how plitidepsin works on the tumor cells.

Trace-Ability, Inc. announced today that the U.S. Food and Drug Administration (FDA) has allowed the first use of its product, Tracer-QC, for release testing of an imaging agent used in Positron Emission Tomography (PET) - [N-13]Ammonia for injection.

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the company is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.

OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the company plans to report long-term clinical benefits in mild to severe knee osteoarthritis (OA) patients who were treated with TPX-100 at the 2018 OARSI annual meeting (Liverpool, U.K., 26-29 April 2018).

Highlights ZW49, its HER2-Targeted Bispecific Antibody Drug Conjugate and Novel ZymeLink™ Platform

This new objective balance measure utilizing a smart phone will be available in May 2018.

Projects include: investigating myelin repair strategies, the role of gut bacteria, and non-pharmaceutical approaches to managing debilitating pain in people with MS